<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="https://sms.carm.es/ricsmur/handle/123456789/17084">
<title>02.01. Área de Salud I Murcia Oeste</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/17084</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/29302"/>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/29298"/>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/29299"/>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/29297"/>
</rdf:Seq>
</items>
<dc:date>2026-11-22T09:03:50Z</dc:date>
</channel>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/29302">
<title>Cancer patient outcomes correlate with activating-KIR/ligand repertoires associated with distinct NK cell transcriptomic profiles</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/29302</link>
<description>Cancer patient outcomes correlate with activating-KIR/ligand repertoires associated with distinct NK cell transcriptomic profiles
Ruiz-Lorente, Inmaculada; Vallejo-Pulido, Andres; López-Abad, Alicia; López-Cubillana, Pedro; Barozi, Victor; Khakoo, Salim-I.; Minguela-Puras, Alfredo; Gimeno-Arias, Lourdes
BACKGROUND: Rates of cancer cure increase; however, recurrence and refractoriness remain clinical challenges that require alternative therapeutic strategies. Natural killer (NK) cells could play a decisive role if their antitumor reactivity can be enhanced. The interaction between killer-cell immunoglobulin-like receptors (KIRs) and their human leukocyte antigen class-I (HLA-I) ligands significantly influences NK-cell education and may impact clinical outcomes in cancer patients. In this study, we evaluated the impact of KIR/HLA-I interactions on the transcriptomic profile of circulating NK-cells and their association with patient outcome. METHODS: KIR and HLA-I genotyping, together with KIR expression analysis in circulating NK cells, were performed in patients with solid and hematologic malignancies (n = 1,153). In addition, single-cell transcriptomic analyses (scRNA-seq) of circulating NK and T lymphocytes were carried out in selected donors with KIR/HLA-I genotypes associated with short and long survival. RESULTS: Activating KIRs (aKIRs), more than inhibitory KIRs, were associated with cancer patient outcomes. The accumulation of aKIR-HLA interactions was related to shorter overall survival, whereas KIR2DS1/C2 interaction, in the absence of other aKIR interactions, was associated with longer survival. Three major NK-cell transcriptional profiles were identified: mature cytotoxic, immature/regulatory, and adaptive cytotoxic. The adaptive-like transcriptional profile was associated with longer survival. CONCLUSIONS: In conclusion, aKIR/HLA-I interactions were associated with cancer patient outcomes. In particular, KIR2DS1/C2 interaction in the absence of other activating signals was associated with adaptive NK-cell transcriptomic profiles and improved survival. Understanding the mechanisms underlying effective NK-cell-mediated tumor immunity may provide new opportunities for patients with refractory tumors.
</description>
<dc:date>2026-12-31T00:00:00Z</dc:date>
</item>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/29298">
<title>Epidemiological and Clinical Characteristics of the Enterovirus D68 Outbreak in Spain in 2024</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/29298</link>
<description>Epidemiological and Clinical Characteristics of the Enterovirus D68 Outbreak in Spain in 2024
Camacho, Juan; García-ibanez, Nerea; Fernández-García, María-Dolores; Biya, Yasmin; Ruiz-de-Pedro, Estrella; Gutierrez, Almudena; Nieto, María-Carmen; Ruiz-García, María-Montserrat; Pastor-Fajardo, María-Teresa; Lagarejos, Eduardo; de-Leonardo-Simon, Carlos; Navascues, Ana; Moreno-Docón, Antonio; Gozalo-marguello, Monica; Berengua, Carla; Antequera, Pedro; Huéscar-Pascual, María-Dolores; Calvo, Cristina; Cabrerizo, María
Enterovirus D68 (EV-D68) is a significant cause of respiratory and neurological disease worldwide. In 2024, Spain experienced its largest recorded EV-D68 outbreak, accounting for 37.4% of all typed EV (294/892). This study describes the epidemiological, clinical, and phylogenetic features of EV-D68 infections. Unexpectedly, EV-D68 infections as it seems were more frequent in adults than in children (57.2% vs. 42.8%, p &lt; 0.05), particularly among individuals &gt; 60 years (38.6%). In 84.9% of cases with an EV-D68 infection, EV-D68 was the sole pathogen detected. Respiratory pathologies predominated (91.9%), with bronchospasm/wheezing episodes and bronchiolitis in children, and pneumonia and exacerbations of chronic obstructive pulmonary disease in older adults (p &lt; 0.05). Older patients showed a more severe clinical profile than pediatric patients, including higher hospitalization rates (79% vs. 59%), longer hospital stays (mean, 10.8 vs. 4.9 days), and more comorbidities (50% vs. 31%) (p &lt; 0.01). Phylogenetic analysis revealed two co-circulating lineages with distinct age-related tropisms: B3.3 mainly affected children (88.5%), whereas the novel A2/D1.1 infected adults predominantly (79.6%), particularly ? 60 years (49.5%) (p &lt; 0.05). This pattern may reflect lineage-specific amino acid substitutions enhancing immune evasion. Neurological disease occurred in only three patients &gt; 60 years infected by the A2/D1.1 lineage, which contained neurovirulent substitutions (I553L, K835E, and T860N). Results support continued genomic and clinical surveillance of EV-D68.
</description>
<dc:date>2026-04-01T00:00:00Z</dc:date>
</item>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/29299">
<title>Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/29299</link>
<description>Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression
Aldamiz-Echevarria, Teresa; Tejerina, Francisco; Fanciulli, Chiara; Díez, Cristina; Pérez, Leire; Bellon, José-María; Espinosa, Nuria; Guillen, Santiago-Moreno; del-Mar-Arcos-Rueda, María; Montero-Alonso, Marta; García-Fraile, Lucio; Asensi, Victor; Fernández-López, Marian; Corona-Mata, Diana; Cabello-Ubeda, Alfonso; Manso, Meritxell-Gavalda; Iribarren, José-Antonio; Pérez-Martínez, Laura; Valls, María-Remedios-Aleman; Portilla-Tamarit, Irene; Peraire, Joaquim; Suarez-García, Ines; Masia, Mar; Núñez-Orantos, María-José; Gutiérrrez-Liarte, Ángela; Imaz, Arkaitz; Hernández-Gutierrez, Cristina; Pitarch, María-Tasias; Rava, Marta
OBJECTIVES: Lymphomas remain among the most frequent HIV-associated malignancies, with risk persisting despite effective virological control. This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non-Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma-related mortality at 1 year and overall survival at 5 years. METHODS: We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV-1 RNA &lt;100 copies/mL within the 6 months prior to and 1 month following lymphoma diagnosis. RESULTS: Among 18 573 PLWH included in CoRIS, 291 developed lymphoma, with virological data available for 245 individuals, of whom 49 (20%) had virological suppression. People with detectable HIV viral load had lower CD4 counts (median 180 cells/mm(3) [IQR 80-330] vs. 371 cells/mm(3) [IQR 202-583], p &lt; 0.001) and more advanced Ann Arbor stage (stage III-IV: 82.0% vs. 64.1%, p = 0.027) compared with those with virological suppression. Despite this, they showed similar treatment response (complete remission: 67.1% vs. 76.2%) and relapse rates (16.3% vs. 18.4%, p = 0.779). Furthermore, virological suppression was not independently associated with 1-year lymphoma-specific or 5-year overall survival. CONCLUSIONS: In PLWH diagnosed with lymphoma, prognosis is independent of HIV virological status at diagnosis. These findings support that lymphoma management in PLWH should be guided by standard oncological criteria, alongside antiretroviral therapy, regardless of HIV viral suppression status.
</description>
<dc:date>2026-08-01T00:00:00Z</dc:date>
</item>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/29297">
<title>The Open Reading Frame 7b of the SARS-CoV-2 Disperse Trans-Golgi and Activate the NLRP3 Inflammasome</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/29297</link>
<description>The Open Reading Frame 7b of the SARS-CoV-2 Disperse Trans-Golgi and Activate the NLRP3 Inflammasome
García-Villalba, Julio; Hurtado-Navarro, Laura; Angosto-Bazarra, Diego; Baroja-Mazo, Alberto; Pelegrín, Pablo
Inflammasomes orchestrate the inflammatory response against bacterial and viral infections, thereby initiating the synthesis of pro-inflammatory cytokines, mainly IL-1? and IL-18. SARS-CoV-2 infection induces an inflammatory response mediated by the activation of NLRP1 and NLRP3 inflammasomes. In this study, we demonstrated that the open reading frame 7b (ORF7b) accessory protein of SARS-CoV-2 induces the NLRP3 inflammasome in a recombinant HEK293T model. This resulted in an increase in the distribution of NLRP3 puncta, ASC-specking cells, and caspase-1 activation. ORF7b expression also induced the dispersion of the trans-Golgi network, a well-known step in the activation of the NLRP3 inflammasome. This study proposes a novel additional mechanism by which SARS-CoV-2 promotes NLRP3 inflammasome activation by ORF7b.
</description>
<dc:date>2026-04-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
